News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Actinium Pharmaceuticals, Inc. Completes Technology Transfer For Manufacturing Of Its Lead Drug Candidate Iomab™-B


12/19/2013 9:33:39 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NEW YORK--(BUSINESS WIRE)--Actinium Pharmaceuticals, Inc. (OTCQB:ATNM.OB) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, has successfully transferred the technology for the manufacture of Iomabâ„¢-B (BC8-I-131), a drug being developed for therapeutic treatment of incurable blood cancers. The Company now intends to complete plans to scale-up, submit an Investigational New Drug (IND) Application to the U.S. Food and Drug Administration and initiate a pivotal Phase 3 clinical trial in 2014.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES